Immungenetics AG   Report issue

For profit Phase 2
Founded: Rostock Germany (2009)

Organization Overview

First Clinical Trial
2017
NCT03417986
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Immungenetics AG